MedTrace Logo

Predictive Value of Early Changes of Chromogranin A Levels in Patients With Neuroendocrine Tumours Treated With PRRT

NCT06183047 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 38

Last updated 2023-12-27

No results posted yet for this study

Summary

The results of the study suggest that an early change in CgA levels might serve as a prognostic factor in NET patients treated with PRRT.

Conditions

  • Early Release of Chromogranin A (CgA)

Interventions

DIAGNOSTIC_TEST

early release of chromogranin A (CgA) in patients with neuroendocrine tumours (NET) treated with peptide receptor radionuclide therapy (PRRT).

early release of chromogranin A (CgA) in patients with neuroendocrine tumours (NET) treated with peptide receptor radionuclide therapy (PRRT).

Sponsors & Collaborators

  • Military Institute od Medicine National Research Institute

    lead OTHER

Principal Investigators

  • Andrzej Mazurek, MD · Military Institute of Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-01
Primary Completion
2023-09-30
Completion
2023-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06183047 on ClinicalTrials.gov